EDEN PRAIRIE, Minn., April 12, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today its commercial expansion into the Hong Kong market through its Asia distributor, Transmedic. Further, Transmedic has confirmed its first commercial orders for both Singapore and Hong Kong.
"Our expansion into the Asian markets is a key factor in our commercialization strategy, and our distribution partner, Transmedic, has flawlessly initiated on executing that strategy,” commented John Erb, chairman and chief executive officer of CHF Solutions. “We believe the heart failure market for patients suffering from fluid overload remains largely untapped in Asia and that the Aquadex FlexFlow system provides a clinically proven alternative therapy option over pharmacotherapy.”
These commercial orders were for both Aquadex FlexFlow consoles and the corresponding disposable products.
About CHF Solutions
CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.
Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
JQA Partners, Inc.
Source: CHF Solutions, Inc.